Is Century Casinos, Inc. (CNTY) a Buy, Sell, or Hold?
Century Casinos, Inc.
NASDAQ:CNTY
$1.26 USD
$0.02 (1.61%)
- Volume
- 65.91K
- Average Volume
- 71.78K
- Market Capitalization
- $35.45M
- P/E Ratio
- -0.65
- Dividend Yield
- 0.00%
- Price Target
- $2.50
- Year High
- $2.85
- Year Low
- $1.23
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.22
| Source | Headline |
|---|---|
|
Century Therapeutics Selected for Oral Presentations of CNTY-813 Preclinical Data at EASD 2026 and Breakthrough T1D® Clinical & Research Congress 2026
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses: globenewswire.com - 2026-07-09 08:00:00 |
|
Despite Fast-paced Momentum, Century Casinos (CNTY) Is Still a Bargain Stock
Century Casinos (CNTY) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices. zacks.com - 2026-06-19 09:56:19 |
|
Is Century Casinos (CNTY) Outperforming Other Consumer Discretionary Stocks This Year?
Here is how Century Casinos (CNTY) and Carter's (CRI) have performed compared to their sector so far this year. zacks.com - 2026-06-17 10:40:32 |
|
New CNTY-813 Preclinical Data Demonstrate Durable Glucose Control, Immune Evasion Under Alloimmune Pressure, and Scalable Manufacturing at ADA 2026
PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the presentation of new preclinical data from CNTY-813, Century's iPSC-derived islet replacement therapy engineered with Allo-Evasion™ 5.0, in an oral presentation at the American Diabetes Association (ADA) 86th Scientific Sessions in New Orleans, Louisiana. globenewswire.com - 2026-06-08 16:05:00 |
|
Century Casinos Announces Appointment to Top Leadership Role in the United States
COLORADO SPRINGS, Colo., May 13, 2026 /PRNewswire/ -- Century Casinos, Inc. (the "Company" or "Century Casinos") (Nasdaq Capital Market®: CNTY) announced today that Lyle Randolph, a long-term regional Vice President and General Manager of the Company, will take over as Executive Vice President of Operations for the United States. prnewswire.com - 2026-05-13 16:30:00 |
|
Century Casinos, Inc. (CNTY) Q1 2026 Earnings Call Transcript
Century Casinos, Inc. (CNTY) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-08 16:21:19 |
|
Century Casinos (CNTY) Reports Q1 Loss, Lags Revenue Estimates
Century Casinos (CNTY) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to a loss of $0.67 per share a year ago. zacks.com - 2026-05-08 08:11:18 |
|
Century Casinos, Inc. Announces First Quarter 2026 Results
All-Time Record First Quarter Net Operating Revenue COLORADO SPRINGS, Colo., May 8, 2026 /PRNewswire/ -- Century Casinos, Inc. (the "Company", "we", "us", or "our") (Nasdaq Capital Market®: CNTY) today announced its financial results for the three months ended March 31, 2026. prnewswire.com - 2026-05-08 06:00:00 |
|
Century Casinos Announces Dates of First Quarter 2026 Earnings Release and Conference Call
COLORADO SPRINGS, Colo., May 1, 2026 /PRNewswire/ -- Century Casinos, Inc. (Nasdaq Capital Market®: CNTY) announced today that the Company will release its earnings for the first quarter 2026 on Friday, May 8, 2026. prnewswire.com - 2026-05-01 08:00:00 |
|
Century Therapeutics Selected for Oral Presentation of CNTY‑813 Preclinical Data at the American Diabetes Association 86th Scientific Sessions
CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 globenewswire.com - 2026-04-30 16:05:00 |
